145433-09-6

Basic information

• Product Name: 3(2H)-Isoxazolone,4-methyl-5-(trifluoromethyl)-(9CI)
• Synonyms: 3(2H)-Isoxazolone,4-methyl-5-(trifluoromethyl)-(9CI)
• CAS NO: 145433-09-6
• Molecular Formula: C5H4F3NO2
• Molecular Weight: 167.0859696
• Product Categories: OXAZOLE
• Mol File: 145433-09-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3(2H)-Isoxazolone,4-methyl-5-(trifluoromethyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3(2H)-Isoxazolone,4-methyl-5-(trifluoromethyl)-(9CI)(145433-09-6)
• EPA Substance Registry System: 3(2H)-Isoxazolone,4-methyl-5-(trifluoromethyl)-(9CI)(145433-09-6)

Safety Data

• Hazardous Substances Data: 145433-09-6(Hazardous Substances Data)

Upstream product

• 145433-08-5 (RS)-2-methyl-3-oxo-4,4,4-trifluorobutyrohydroxamic acid 
• 344-00-3 ethyl 2-methyl-4,4,4-trifluoroacetoacetate 

Relevant articles and documents

Synthesis and pharmacology of (RS)-2-amino-3-(3-hydroxy-5-trifluoromethyl-4-isoxazolyl)propionic acid, a potent AMPA receptor agonist

Three isoxazole bioisosteres of glutamic acid derived from the specific AMPA receptor agonist (RS)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) were synthesized and tested electrophysiologically and in different receptor binding systems. (RS)-2-Amino-3-(3-hydroxy-5-trifluoromethyl-4-isoxazolyl)propionic acid (trifluoro-AMPA, 8) showed more potent agonist activity (EC50 2.3 μM) and lower affinity (IC50 0.08 μM) for AMPA receptors than AMPA itself (EC50 3.5 μM and IC50 0.04 μM, respectively). Like AMPA, trifluoro-AMPA (8) did not bind significantly to N-methyl-D-aspartic acid (NMDA) receptor sites, but trifluoro-AMPA (8) was more potent as an inhibitor of [3H]kainic acid ([3H]KAIN) binding (IC50 7.1 μM) than AMPA (IC50 32 μM). (RS)-2-Amino-3-(3-chloro-5-methyl-4-isoxazolyl)propionic acid (14), the 3-chloro analogue of AMPA, and the isomeric compound (RS)-2-amino-3-(3-chloro-4-methyl-5-isoxazolyl)propionic acid (15), did not show significant neuroexcitatory effects at or affinities for AMPA, NMDA, or KAIN receptor sites.

BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS

The invention relates to novel bicyclononene derivatives of Formula (I); and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.